Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hypomethylating Agents”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05442216
What this trial is testing

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Who this might be right for
Acute Myeloid Leukemia
Joshua Zeidner 53
Testing effectiveness (Phase 2)Ended earlyNCT03593915
What this trial is testing

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Who this might be right for
Myelodysplastic Syndromes (MDS)
Sumitomo Pharma America, Inc. 20
Not applicableActive Not RecruitingNCT03789981
What this trial is testing

Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 75
Testing effectiveness (Phase 2)WithdrawnNCT06597734
What this trial is testing

Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Who this might be right for
Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Not applicableUnknownNCT04454580
What this trial is testing

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid Leukemia, AdultHypomethylating AgentsVenetoclax
Ospedale Maggiore Di Trieste 15
Testing effectiveness (Phase 2)Ended earlyNCT02929498
What this trial is testing

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromeMyelodysplastic Syndromes
GlaxoSmithKline 7
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07060001
What this trial is testing

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukaemia (AML)
The Methodist Hospital Research Institute 112
Testing effectiveness (Phase 2)Study completedNCT04273802
What this trial is testing

CPX-351 in Higher Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 40
Testing effectiveness (Phase 2)Study completedNCT00321711
What this trial is testing

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Who this might be right for
MDSMyelodysplastic SyndromesThrombocytopenia
Amgen 69
Early research (Phase 1)Ended earlyNCT02721875
What this trial is testing

Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Boehringer Ingelheim 1
Early research (Phase 1)Looking for participantsNCT03896269
What this trial is testing

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Who this might be right for
Blasts 10-19 Percent of Bone Marrow Nucleated CellsBlasts More Than 5 Percent of Bone Marrow Nucleated CellsHigh Risk Chronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 38
Large-scale testing (Phase 3)Study completedNCT02907359
What this trial is testing

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Astex Pharmaceuticals, Inc. 417
Testing effectiveness (Phase 2)UnknownNCT01673308
What this trial is testing

Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Ulsan University Hospital 35
Not applicableWithdrawnNCT02863458
What this trial is testing

DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
The Cleveland Clinic
Testing effectiveness (Phase 2)WithdrawnNCT01520805
What this trial is testing

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Cornerstone Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT03946670
What this trial is testing

MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 127
Not applicableStudy completedNCT01595295
What this trial is testing

Registry on Hypomethylating Agents in Myeloid Neoplasms

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromesAcute Myeloid Leukemia
Arbeitsgemeinschaft medikamentoese Tumortherapie 1,500